Viral Vector Delivery of FMRP for Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively translate molecular mechanisms targeting RNA binding protein FMRP into therapeutic strategies for Fragile X syndrome, Down syndrome, and Alzheimer's disease, leading to a lack of effective treatments for these conditions.
Innovation Solution
The use of expression vectors, such as lentiviral, adenoviral, or adeno-associated viral vectors, to increase the expression of Fragile X Mental Retardation Protein (FMRP) in cells, thereby reducing levels of DYRK1A and APP proteins, which are associated with these disorders, and modulating the expression of other proteins like KDM1A and HTT to treat developmental and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If molecular mechanisms targeting FMRP are used as therapeutic approaches, then therapeutic potential is improved, but translation into effective treatments has failed
Solution Approach 1:
The patent uses viral vectors (lentiviral, adenoviral, adeno-associated viral vectors) as intermediaries to deliver FMRP polynucleotide sequences into target cells. These vectors serve as mediators between the therapeutic FMRP gene and the cellular machinery, enabling effective gene delivery and expression that direct administration cannot achieve.
Solution Approach 2:
The patent creates copies of the FMRP polynucleotide sequence and introduces them into cells through viral vectors. These copied genetic sequences are then expressed to produce FMRP protein, effectively replacing the lost or insufficient endogenous FMRP in patients with Fragile X syndrome, Down syndrome, or Alzheimer's disease.
2Quantity of substance
If FMRP expression is increased to treat disorders, then protein levels are improved, but delivery to target cells remains challenging
Solution Approach 1:
Viral vectors act as intermediaries to overcome the challenge of delivering FMRP polynucleotide sequences into target cells. The viral vectors have evolved mechanisms to efficiently enter cells and deliver genetic material, solving the delivery problem that direct gene administration cannot resolve.
Solution Approach 2:
The patent employs composite viral vector systems that combine different viral components (lentiviral, adenoviral, or adeno-associated viral vectors) with the FMRP polynucleotide sequence. These composite structures leverage the advantageous properties of different viral vectors to achieve efficient delivery and sustained expression of FMRP.
3Productivity
If viral vectors are used to deliver FMRP, then gene delivery efficiency is improved, but vector selection and optimization complexity increases
Solution Approach 1:
The patent employs multiple types of viral vectors (lentiviral, adenoviral, adeno-associated viral vectors) that can serve universal purposes for delivering the FMRP polynucleotide sequence. Each vector type offers different advantages but all achieve the core function of gene delivery, providing flexibility without requiring entirely separate systems for different applications.
Solution Approach 2:
The patent optimizes various parameters of the viral vectors including choice of vector type, promoter sequences, and polynucleotide constructs to achieve efficient delivery and expression. By adjusting these parameters, the system balances delivery efficiency with safety and applicability to different patient populations and administration routes.
Data Source
AI summary
Described and featured are compositions and methods for treating developmental, neurodevelopmental (e.g., Fragile X syndrome (FXS) or Down syndrome (DS)), or neurodegenerative diseases or disorders (e.g., Alzheimer's disease (AD)) by increasing expression of Fragile X Mental Retardation Protein (FMRP) in patients having or having a propensity to develop such diseases or disorders.